Oral Contraceptives in Polycystic Ovary Syndrome: Risk-Benefit Assessment

Bulent O. Yildiz, M.D.


Semin Reprod Med. 2008;26(1):111-120. 

In This Article

Current Contraindications to the Use of OCPs

The World Health Organization (WHO); has developed an evidence-based guideline for the use of OCPs.[35] This document, based on systematic reviews of available clinical and epidemiologic research, is updated regularly. The most recent version is published in 2004. Absolute and relative contraindications to the use of low-dose combined OCPs according to the WHO guideline are shown in Table 1 .


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: